ClinicalTrials.gg
CompletedNCT02332954AtWoRCUpdated Jan 30, 2018

Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine

A Phase 4 interventional study of vortioxetine in Major Depressive Disorder, sponsored by Lundbeck Canada Inc.. Completed at 26 sites in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-01-30.

Sponsored by Lundbeck Canada Inc. (part of H. Lundbeck A/S) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
226
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
31st of 54
226 · median 413
Started
2015
with 2 others
Phase 4
13 of 54
none open now
Registered
29th of 54
by date
Lead sponsor
1 of 54
Lundbeck Canada Inc.

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 31st largest by enrollment, is one of 3 that started in 2015, is one of 13 in phase 4, and was the 29th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of the study is to describe the association/correlation between change in patient-reported cognitive symptoms and work productivity in gainfully employed patients receiving vortioxetine for a Major Depressive Episode (MDE).

Read the detailed description

This is an interventional, Canadian, multi-site, open-label, single cohort, flexible-dose study. The study will emulate a naturalistic real-life setting. Investigators will include Primary Care Physicians and Psychiatrists working in outpatient clinics. The study will include adult patients diagnosed with MDD according to the DSM-5™. Approximately 200 patients will be enrolled in the study. There will be approximately 100 patients who receive vortioxetine as a first treatment for the current MDE and 100 patients switched to vortioxetine due to inadequate response to their current antidepressant medication treatment. All patients will be treated with vortioxetine as per the product monograph, and at the doses determined appropriate by the investigator. The total study duration from Baseline to the end of follow-up will be approximately 56 weeks.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Depression
  • Major Depressive Disorder
  • Cognition
  • Cognitive symptoms
  • vortioxetine
  • real life
  • naturalistic
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient is a man or woman, aged ≥18 years and \<65 years (In the province of British Columbia, the patient must be aged 19 years or older in order to give )
  • The patient is engaged in volunteer work or gainful employment (working ≥20 hours per week) or is enrolled full-time in post-secondary studies or vocational training.
  • The patient is an outpatient consulting a Primary Care Physician or a Psychiatrist.
  • Patients must have a diagnosis of MDD according to the , 5th Edition (DSM-5™) classification code 296.3x.
  • The current MDE is confirmed by the investigator.
  • The reported duration of the current MDE is at least 3 months.
  • The patient has a Baseline score ≥15 on the QIDS-SR.
  • The patient reports at least a minimal level of cognitive symptoms as defined by Baseline score of ≥30 on the PDQ-D-20.
  • The patient is capable of communicating with the site personnel and is able to conduct the digit-symbol substitution test (DSST).

Exclusion criteria

Exclusion Criteria:

  • The patient score is >69 on the DSST at Screening/Baseline.
  • The patient is, in the opinion of the investigator, not able to complete all the study assessments including, but not limited to, patient-reported assessments and the DSST.
  • The patient has a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features.
  • The current depressive symptoms are considered by the investigator to have been resistant to 2 adequate antidepressant treatments of at least 6 weeks duration each at the maximum recommended dose (according to Canadian labeling).

Other protocol defined inclusion and exclusion criteria do apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
226 participants (actual)

Study arms

  • Other
    vortioxetine naive

    vortioxetine 10 mg 100 patients with Major Depressive Disorder who have not been treated with another antidepressant for the current MDE

    Drug: vortioxetine

  • Other
    Switch

    vortioxetine 10 mg 100 patients with Major Depressive Disorder that require a switch from their current antidepressant due to inadequate response

    Drug: vortioxetine

Interventions

  • The starting and recommended dose of vortioxetine is 10 mg once daily; film-coated 10 mg tablets for oral use once daily for 52 weeks.Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily.

    Also known as: Trintellix

06

What researchers measure

Primary outcomes

  1. the association/correlation between changes in patient-reported cognitive symptoms and work productivity. (Perceived Deficit Questionnaire-Depression)

    Mean change from Baseline to Week 12 in patient-reported cognitive symptoms as measured by Perceived Deficit Questionnaire-Depression-20 questions (PDQ-D-20) and work productivity as measured by Work Limitations Questionnaire (WLQ) in gainfully employed patients receiving vortioxetine for a Major Depressive Episode (MDE).

    Time frame: 12 weeks

Secondary outcomes

  1. Cognitive function (PDQ-D-20)

    Mean change from baseline in cognitive symptoms as measured by PDQ-D-20.

    Time frame: 12 and 52 weeks

  2. Cognitive function (Digit Symbol Substitution Test (DSST)

    Mean change from baseline in cognitive symptoms as measured by Digit Symbol Substitution Test (DSST).

    Time frame: 12 and 52 weeks

  3. Work productivity (WLQ)

    mean change from baseline in work productivity as measured by WLQ.

    Time frame: 12 and 52 weeks

  4. Work productivity (Work Productivity and Activity Impairment (WPAI) questionnaire)

    mean change from baseline in work productivity as measured by Work Productivity and Activity Impairment (WPAI) questionnaire.

    Time frame: 12 and 52 weeks

  5. Work productivity (World Health Organization Disability Assessment Schedule-12 questions (WHODAS-12)

    mean change from baseline in work productivity as measured by World Health Organization Disability Assessment Schedule-12 questions (WHODAS-12).

    Time frame: 12 and 52 weeks

  6. Work productivity (Sheehan Disability Scale (SDS)

    mean change from baseline in work productivity as measured by Sheehan Disability Scale (SDS).

    Time frame: 12 and 52 weeks

  7. Depressive symptoms (Quick Inventory of Depression Symptomatology-Self Report (QIDS-SR)

    mean change from baseline in depressive symptoms as measured by Quick Inventory of Depression Symptomatology-Self Report (QIDS-SR).

    Time frame: 12 and 52 weeks

  8. Depressive symptoms (Clinical Global Impression-Improvement (CGI-I) score)

    mean change in depressive symptoms as measured by Clinical Global Impression-Improvement (CGI-I) score.

    Time frame: 12 and 52 weeks

  9. Depressive symptoms (Clinical Global Impression-Severity (CGI-S)

    mean change from baseline in depressive symptoms as measured by Clinical Global Impression-Severity (CGI-S).

    Time frame: 12 and 52 weeks

07

Study locations

26 sites
  • CA004
    Edmonton, Alberta T6L 6W6, Canada
  • CA005
    Kelowna, British Columbia V1Y 1Z9, Canada
  • CA006
    St. John's, Newfoundland and Labrador A1E 2C2, Canada
  • CA007
    Halifax, Nova Scotia B3S 1M7, Canada
  • CA016
    Burlington, Ontario L7R 4E2, Canada
  • CA013
    Chatham, Ontario N7L 1C1, Canada
  • CA010
    Corunna, Ontario N0N 1G0, Canada
  • CA012
    Fort Erie, Ontario L2A 1Z3, Canada
  • CA017
    Hamilton, Ontario L8M 1K7, Canada
  • CA026
    Hamilton, Ontario L8N 4A6, Canada
  • CA011
    London, Ontario N6H 4P2, Canada
  • CA003
    Mississauga, Ontario L5M 4N4, Canada
  • CA008
    Sarnia, Ontario N7T 4X3, Canada
  • CA009
    Sarnia, Ontario N7T 4X3, Canada
  • CA015
    St. Catharines, Ontario L2T 3Y4, Canada
  • CA022
    Montreal, Quebec H1N 3V2, Canada
  • CA020
    Montreal, Quebec H2R 1V6, Canada
  • CA023
    Montreal, Quebec H3A 0G6, Canada
  • CA018
    Pointe-Claire, Quebec H9R 4S3, Canada
  • CA024
    St-Jean-sur-Richelieu, Quebec J2W 1J1, Canada
  • CA030
    Victoriaville, Quebec G6P 6P6, Canada
  • CA027
    Westmount, Quebec H4A1S9, Canada
  • CA028
    Saskatoon, Saskatchewan S7K 3H3, Canada
  • CA019
    Quebec, G1G 3Y8, Canada
  • CA021
    Quebec, G3K 2P8, Canada
  • CA029
    Quebec, G3K 2P8, Canada
08

References and documents

Publications

  • Chokka P, Bougie J, Proulx J, Tvistholm AH, Ettrup A. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study. CNS Spectr. 2019 Dec;24(6):616-627. doi: 10.1017/S1092852919000786. PubMed 30802419 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Jul 2017 and a completion of Jul 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2015
First posted
Jan 7, 2015
Start
Feb 2015
Primary completionActual
Jul 6, 2017
CompletionActual
Jul 6, 2017
Last update
Jan 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02332954
Responsible party
Sponsor
First posted
Jan 7, 2015
Start date
Feb 2015
Primary completion
Jul 6, 2017
Completion
Jul 6, 2017
Last update
Jan 30, 2018

Study contacts

Pratap Chokka, M.D.
principal investigator · Chokka Center for Integrative Health

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion